T2	Participants 226 281	patients with acquired immunodeficiency syndrome (AIDS)
T1	Participants 52 99	cytomegalovirus retinitis in patients with AIDS
T3	Participants 575 680	two doses (165-microg/injection [35 eyes, 30 patients] and 330-microg/injection [153 eyes, 120 patients])
T4	Participants 685 747	two 330-microg/injection dose schedules of different intensity
